HomeAbout

TL;DR CNBC


Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue - TL;DR CNBC

Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue

Publishing timestamp: 2024-02-06 12:17:42


Summary

Eli Lilly reported fourth-quarter revenue and adjusted earnings that exceeded expectations. The strong launch of their weight loss drug, Zepbound, and higher prices for their diabetes treatment, Mounjaro, contributed to the positive results. However, there were mentions of stock falling and lower sales for other products. Eli Lilly also issued its full-year forecast for 2024, which was generally in line with expectations. The company expects revenue growth to accelerate in the second half of the year.


Sentiment: MIXED

Tickers: LLY

Keywords: breaking newsbiotechnologyearningspharmaceuticalshealth care industryeli lilly and cobusiness newsbusinessbiotech and pharmaceuticals

Source: https://www.cnbc.com/2024/02/06/eli-lilly-lly-earnings-q4-2023.html


Developed by Leo Phan